OT
"worth owning"
It's always a matter of how much you have to pay.
I can't flip IPOs, and I don't feel like playing the "shares, shares, who has the shares" shell game that has characterized the biotech aftermarket for years.
I like a lot of the "phenotyping" companies, but I'm not willing to pay even top-of-range prices, much less those that are often achieved in short order.
Love SGMO, the company. Hated SGMO, the stock.
Love LEXG, the company. Hated, LEXG the stock. Waited for it to come down and bought some. Hate LEXG, the stock, even more than before.
<g> |
